TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04086953

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Incremental shuttle walk test
Description: Incremental walking test suitable for patients with chronic respiratory diseases. To perform this test, it is necessary to have a 10-meter walking corridor. The walking speed is dictated by a sound signal previously recorded. Every minute, the time between each beep is decreased and therefore the walking speed increased. The increment is 0.17m / sec every minute. Shifting to a higher speed is indicated by a triple beep. At most, the ISWT includes 12 speed levels.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Incremental shuttle walk test
Description: Incremental walking test suitable for patients with chronic respiratory diseases. To perform this test, it is necessary to have a 10-meter walking corridor. The walking speed is dictated by a sound signal previously recorded. Every minute, the time between each beep is decreased and therefore the walking speed increased. The increment is 0.17m / sec every minute. Shifting to a higher speed is indicated by a triple beep. At most, the ISWT includes 12 speed levels.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endurance shuttle walk test
Description: Constant load endurance running test performed on the same 10 meter run as the ISWT.~The patient is walking at a constant speed imposed by the audio beeps as for the ISWT. The objective of this test is to maintain the imposed walking speed as long as possible. The speed is calculated from the ISWT.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endurance shuttle walk test
Description: Constant load endurance running test performed on the same 10 meter run as the ISWT.~The patient is walking at a constant speed imposed by the audio beeps as for the ISWT. The objective of this test is to maintain the imposed walking speed as long as possible. The speed is calculated from the ISWT.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Respiratory Functional Assessment
Description: Forced vital capacity, total lung capacity, forced expiratory volume measured during the first second of forced expiration, and carbon monoxide diffusion capacity will be measured by plethysmographic examination and spirometry.
Study: NCT03543202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local infiltration anesthesia
Description: will receive 20ml bupivacaine for local infiltration anesthesia and intravenous patient controlled analgesia

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravenous patient controlled analgesia
Description: will not receive any regional anesthetic intervention will receive intravenous patient controlled analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous patient controlled analgesia
Description: will not receive any regional anesthetic intervention will receive intravenous patient controlled analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous patient controlled analgesia
Description: will not receive any regional anesthetic intervention will receive intravenous patient controlled analgesia
Study: NCT00713947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: during one week for the active treatments
Description: during one week for the active treatments placebo during 25 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 6 months at 20 mg
Study: NCT01719952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: IV carbetocin 100mcg, only in selected patient given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.~pitocin 5 IU also given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
Study: NCT00713947

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Formula 515
Description: 26 weeks, one tablet per day
Study: NCT03364660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acute epidural stimulation for cardiovascular stability
Description: Eligible participants will be implanted with 16-electrode epidural array and epidural stimulator in the spinal cord. Participants received mapping for cardiovascular stability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long Term Epidural Stimulation for Cardiovascular Stability
Description: Participants undergo approximately 4 months of epidural stimulation for cardiovascular stability, daily.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Participants undergo approximately 4 months of epidural stimulation for voluntary movement.
Description: Participants undergo approximately 4 months of epidural stimulation for voluntary movement 4-7 days weekly.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long Term Epidural Stimulation for Cardiovascular Stability plus Stand Training
Description: Participants undergo approximately 4 months of epidural stimulation for cardiovascular stability, daily. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Participants undergo approximately 4 months of epidural stimulation for voluntary movement plus stand training.
Description: Participants undergo approximately 4 months of epidural stimulation for voluntary movement, 4-7 days weekly. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly.
Study: NCT02490501

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SC0806 and rehabilitation

Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation only
Study: NCT02967315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging (CMRI)
Description: There will be 2 CMRIs. The first one will be patient's routine clinically schedule CMRI after the patient has fasted for 12 hours.This CMRI uses contrast.~The second CMRI will be the research CMRI after the fluid administration. This CMRI does not use contrast.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous line placement
Description: An ultrasound guided central line catheter will be placed in the internal jugular vein (IJV) under local anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest X-ray
Description: A chest X-ray will be performed for safety reasons to rule out pneumothorax (\< 1% risk) after central line placement.
Study: NCT01719952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 5 IU given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
Study: NCT02395120

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard letter
Description: Standard referral letter according to Ohio Department of Health Bureau guidelines. This letter is consistent with others used across the country.
Study: NCT02967315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid administration
Description: Administration of 15cc/kg of normal saline for fluid hydration through peripheral IV that is placed for the MRI contrast administration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: One to two teaspoons of blood will be drawn for basic metabolic panel.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pregnancy test
Description: A urine pregnancy test will be performed in female subjects.
Study: NCT02395120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention letter
Description: Referral letter based on the Common Sense Model of Self-Regulation (CSM). The letter includes the cognitive dimensions of the CSM (identity, cause, timeline, consequences and control).
Study: NCT02967315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: 12 lead ECG
Study: NCT01532856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide, Cyclophosphamide, Dexamethasone
Description: Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Cyclophosphamide - 50mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally(two pulses the first two cycles in days 1-4 and 15-18 and then a single pulse in each other cycle) during 9 cycles of 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide, Dexamethasone
Description: Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally, in three pulses (days 1 to 4, 9 to 12 and 17 20) odd cycles and a single pulse treatment in pairs cycles, during 9 cycles of 28 days each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide, Melphalan, Prednisone
Description: thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle; melphalan - 4 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle; prednisone - 40 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle
Study: NCT02318446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Test group(n= 24) Existing Anti-epileptic Drugs + Oral Folic acid 1mg tablet daily for 1month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saccharine
Description: Placebo group(n=12) Existing Anti-epileptic Drugs + Oral saccharine 10 mg tablet daily for 1month
Study: NCT01441765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT-011
Description: CT-011 at 3 mg/kg IV for 4 cycles of 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT-011
Description: CT-011 at 3 mg/kg IV for 4 cycles of 6 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC/RCC fusion vaccine
Description: Vaccination once per cycle on Day 8 of treatment cycles 2-4
Study: NCT03577496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peppermint oil
Description: A cotton ball with three drops of peppermint oil will be waved under the patient's nares.
Study: NCT02473939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VR942 delivered via a Vectura Dry Powder Inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VR942 delivered via a Vectura Dry Powder Inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VR942 delivered via a Vectura Dry Powder Inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VR942 delivered via a Vectura Dry Powder Inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VR942 delivered via a Vectura Dry Powder Inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo delivered via a Vectura Dry Powder Inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo delivered via a Vectura Dry Powder Inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo delivered via a Vectura Dry Powder Inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo delivered via a Vectura Dry Powder Inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo delivered via a Vectura Dry Powder Inhaler
Study: NCT00205023

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonohysterography
Description: SHG during surgery for endometrial cancer.
Study: NCT04570670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monomethyl fumarate 190 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl fumarate 240 mg
Study: NCT03771560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: subject will take folinic acid daily for 12 weeks
Study: NCT02756143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate.
Study: NCT04615403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost
Description: Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision
Study: NCT03515005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay Health Advisor
Description: Patients will meet regularly Lay Health Advisors who will address the social context of their hypertension.
Study: NCT01104805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES)
Description: Participants will received modified treatment-as-usual plus the computerized psychosocial intervention (Therapeutic Education System), including contingency management. Participants will be asked to use the self-directed TES intervention twice weekly and will be asked to complete 2 modules during each session (for a total of 4 modules per week) during the 12-week intervention. Participants will receive incentives contingent primarily upon abstinence from drugs of abuse and, secondarily, upon completion of TES modules.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment-as-Usual (TAU)
Description: Participants in this condition will receive TAU, consisting of standard treatment offered at each collaborating CTP and will reflect the model of treatment typically provided to most individuals in outpatient, community-based substance abuse treatment settings in the U.S. These sessions will consist of a combination of group and individual counseling.
Study: NCT02478424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Patients will receive standard GVHD prophylaxis consisting of cyclosporine A twice daily starting on day -1 with target trough levels of 200-400 ng/mL and a short course of methotrexate (15 mg/ m2 on day 1 and 10 mg/ m2 on days days 3 and 6). Patients transplanted from unrelated donors will receive ATG Fresenius at a low dose of 5 mg/kg on days -3 to -1.~Patients will be given oral CBD 150 mg BID starting 7 days before transplantation until day 100.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study: NCT03089723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Description: Answer Visual Analog Scale (VAS) questionnaire at baseline, 1 month, 3 months and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Description: Answer Visual Analog Scale (VAS) questionnaire at baseline, 1 month, 3 months and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Range of Motion (ROM)
Description: submitted to ROM at at baseline, 1 month, 3 months and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Range of Motion (ROM)
Description: submitted to ROM at at baseline, 1 month, 3 months and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palmar grip strength
Description: submitted to palmar grip strength at at baseline, 1 month, 3 months and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palmar grip strength
Description: submitted to palmar grip strength at at baseline, 1 month, 3 months and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lateral grip strength
Description: submitted to lateral grip strength at at baseline, 1 month, 3 months and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lateral grip strength
Description: submitted to lateral grip strength at at baseline, 1 month, 3 months and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulp-pulp pinch strength
Description: submitted to pulp-pulp pinch strength strength at at baseline, 1 month, 3 months and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulp-pulp pinch strength
Description: submitted to pulp-pulp pinch strength strength at at baseline, 1 month, 3 months and 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavage with physiologic saline solution
Description: Joint lavage with physiologic saline solution. After emptying of the joint, 1mL saline solution will be injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavage with physiologic saline solution and Osteonil® Mini
Description: Joint lavage with physiologic saline solution and Osteonil® Mini

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quick Dash
Description: Answer Quick Dash questionnaire at baseline, 1 month, 3 months and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quick Dash
Description: Answer Quick Dash questionnaire at baseline, 1 month, 3 months and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sollerman Test
Description: Perform Sollerman Test at baseline, 1 month, 3 months and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sollerman Test
Description: Perform Sollerman Test at baseline, 1 month, 3 months and 6 months
Study: NCT01020630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be orally administered at 25 mg once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
Study: NCT02395120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention letter
Description: Referral letter based on the Common Sense Model of Self-Regulation (CSM). The letter includes the cognitive dimensions of the CSM (identity, cause, timeline, consequences and control).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced intervention letter
Description: Reduced (removing text corresponding to timeline) CSM theory-based referral letter. The letter includes the remaining cognitive dimensions of the CSM (identity, cause, consequences and control).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced intervention letter
Description: Reduced (removing text corresponding to timeline) CSM theory-based referral letter. The letter includes the remaining cognitive dimensions of the CSM (identity, cause, consequences and control).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIG
Description: Dental information guide (DIG) to reinforce/change illness perception, knowledge about dental caries, and resources to seek care. DIG is a brochure with illustrations which provides myths and facts about dental caries, hints for getting dental care, making appointments and Medicaid access, transportation and dentist availability resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced DIG
Description: Text and illustrations related to the timeline construct of the CSM have been removed in the reduced dental information guide.
Study: NCT02816580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Study: NCT00377234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 35mg po weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 3 months
Study: NCT03801239

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic Study
Description: during visit Week 0 patients had urodynamic study

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic Study
Description: during visit Week 0 patients had urodynamic study

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic Study
Description: during visit Week 0 patients had urodynamic study

Intervention type: DIAGNOSTIC_TEST
Intervention: OABSS questionnaire fulfilment
Description: during visit Week 0 and Week 2 patients fulfilled OABSS

Intervention type: DIAGNOSTIC_TEST
Intervention: OABSS questionnaire fulfilment
Description: during visit Week 0 and Week 2 patients fulfilled OABSS

Intervention type: DIAGNOSTIC_TEST
Intervention: OABSS questionnaire fulfilment
Description: during visit Week 0 and Week 2 patients fulfilled OABSS

Intervention type: DIAGNOSTIC_TEST
Intervention: UDI-6 questionnaire fulfilment
Description: during visit Week 2 patients fulfilled UDI-6 questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: UDI-6 questionnaire fulfilment
Description: during visit Week 2 patients fulfilled UDI-6 questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: UDI-6 questionnaire fulfilment
Description: during visit Week 2 patients fulfilled UDI-6 questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: IIQ-7 questionnaire fulfilment
Description: during visit Week 2 patients fulfilled IIQ-7 questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: IIQ-7 questionnaire fulfilment
Description: during visit Week 2 patients fulfilled IIQ-7 questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: IIQ-7 questionnaire fulfilment
Description: during visit Week 2 patients fulfilled IIQ-7 questionnaire
Study: NCT04534595

Intervention type: OTHER
Intervention: COVID-19
Description: To study the experience of students and their families during the COVID-19 pandemic an online questionnaire will be utilized. This COVID-19 questionnaire will be administered at three time points: baseline, 6 months upon completion of the baseline questionnaire, and 12 months upon completion of the baseline questionnaire.
Study: NCT04593446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Sulfate Tablet(ORA·FANGⓇ)
Description: Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery~Subjects who are randomized into comparator will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Picosulfate Solution(PicosolutionⓇ)
Description: Sodium Picosulfate Solution(PicosolutionⓇ)
Study: NCT01020630

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be orally administered once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.